erlotinib hydrochloride has been researched along with Thyroid Cancer, Anaplastic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, YS; Jeon, MJ; Kim, TY; Kim, WB; Kim, WG; Kwon, H; Shong, YK; You, MH | 1 |
1 other study(ies) available for erlotinib hydrochloride and Thyroid Cancer, Anaplastic
| Article | Year |
|---|---|
Effects of dabrafenib and erlotinib combination treatment on anaplastic thyroid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Mitogen-Activated Protein Kinase Kinases; Mutation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | 2022 |